Kalsiom

Kalsiom is an early-stage biotech company pioneering a novel approach to treating autoimmune diseases by targeting calcium signaling in immune cells. Leveraging unique scientific expertise in calcium signaling and antibody development, the company aims to create first-in-class therapies for conditions with high unmet need, such as those involving B-cell dysfunction. Currently in the preclinical discovery phase, Kalsiom is a private, pre-revenue entity building its foundational technology and pipeline. The company's success hinges on validating its novel mechanism and advancing candidates into clinical development.

Discovery and development of monoclonal antibodies that modulate calcium signaling pathways in lymphocytes (particularly B-cells) to treat autoimmune disorders.

Kalsiom competes in the crowded autoimmune disease space dominated by large pharma (e.g., AbbVie, Johnson & Johnson, Roche) with blockbuster biologics and a pipeline of next-generation therapies. Its direct competitors include other biotechs developing novel B-cell modulators (e.g., targeting BAFF, APRIL, or other signaling pathways). Its unique angle is the specific focus on calcium signaling, a pathway less exploited therapeutically in autoimmunity.